Janus Kinase Inhibitor Treatment Outcomes in Cutaneous Histiocytosis: A Systematic Review

Cutaneous histiocytoses represents a group of rare skin disease characterized by small brown or erythematous papules, with overlying nodules and crusting. Refractory cases are often treated with immunosuppressive therapy, however many cases still lead to poor treatment outcomes. Here, we review the outcomes of Janus Kinase inhibitors (JAKi), a novel therapy in cutaneous histiocytosis refractory to traditional systemic therapies.